Skip to main content
Hit enter to search or ESC to close
Close Search
MedincellMedincellMedincell
search
Menu
  • About Us
    • Impact companyPurposeful innovation coupled with a responsible company model can positively impact Global Health
    • Our peopleOur strength: valuing and nurturing our team’s entrepreneurial spirit, expertise, and dedication
    • Leadership TeamSeasoned leaders unite to tackle global health challenges
  • Science
    • UZEDY®Relapse prevention long-acting treatment for schizophrenia
    • R&D PipelineAdvancing therapeutic care with precision Delivery
    • BEPO® TechnologyOur technology platform to develop long-acting treatments
    • PublicationsFacilitate collaboration with our collection of scientific articles and presentations
  • Responsibility
    • Our commitmentsTransforming global health with purposeful innovation
    • Code and policiesHigh standards for all company’s stakeholders
    • 2026 ESG reportSocial and environmental information about the company and its activities
  • Careers
    • Our vision & our valuesSee how our HR vision and values shape a dynamic workforce
    • Work environment & benefitsExplore the benefits and environment driving our team’s success
    • Join usEmbark on a career journey where your talents meet opportunity
  • News & events
    • NewsroomLatest updates and announcements, the gateway to all press releases
    • EventsEarnings calls, conferences, General Meeting: live and replay
  • Investors
    • OverviewAll information and news about Medincell stock
    • Reports & regulated informationFinancial reports, operational updates, and shareholder information
    • General MeetingAll documents related to the Medincell Shareholders’ Meetings
    • Leadership teamSeasoned leaders unite to tackle global health challenges
  • Contact
  • EN
  • FR
  • search
Category

General

MedinCell partner Teva announces successful launch of UZEDY™

September 12, 2023

US Biopharma Financial & IR Strategy Veteran Dr Grace Kim joins MedinCell

September 6, 2023
September 6, 2023

MedinCell to take part in Jefferies Global Healthcare Conference – London, 14-16 November

August 31, 2023

Participation terms in the Combined General Meeting

August 21, 2023
August 21, 2023

MedinCell’s partner Teva announces successful launch of UZEDY™

August 2, 2023
August 2, 2023

MedinCell has received the last tranche of €10m from the European Investment Bank (EIB) loan

July 31, 2023
July 31, 2023

MedinCell announces the availability of its 2022-23 Universal Registration Document including the Annual Financial Report

July 31, 2023
July 31, 2023

MedinCell announces its full year financial results April 2022 – March 2023

June 26, 2023
June 26, 2023

MedinCell will publish its annual results (April 2022-March 2023) on June 26, 2023

June 5, 2023
June 5, 2023

Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile

May 22, 2023
May 22, 2023
  • Previous
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 22
  • Next

Articles récents

  • Videoconference • Annual results 2025-26
  • Medincell’s Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026
  • Medincell to Participate in Upcoming Investor Conferences
  • Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting
  • Medincell appoints Edna Venneker, MD, as Chief Medical Officer

Commentaires récents

No comments to show.

About us

Impact company
Our people
Leadership Team

Science

UZEDY®
R&D Pipeline
BEPO® Technology
Publications

Careers

Our vision & our values
Work environment & benefits
Join us

Responsability

Our commitments
Code and policies
2026 ESG report

News & events

Newsroom
Events

Investors

Overview
Reports & regulated information
General Meeting
Leadership team

Ressources & contact

Contact
Ethics line
Legal notices
Privacy policy

© 2026 Medincell. All rights reserved.

Website by ScreenUp

Close Menu
  • Home
  • About Us
    • Impact company
    • Our people
    • Leadership team
  • Science
    • UZEDY®
    • R&D Pipeline
    • BEPO® Technology
    • Publications
  • Responsibility
    • Our commitments
    • Code and policies
    • 2025 ESG Report
  • Careers
    • Our vision & our values
    • Work environment & benefits
    • Join us
  • News & events
    • News
    • Events
  • Investors
    • Overview
    • Regulated information
    • General Meeting
    • Leadership team
  • Contact
  • FR